RESUMEN
The nuclear receptor superfamily comprises ligand-regulated transcription factors that control various developmental and physiological pathways. These receptors share a common modular structure and regulate gene expression through the recruitment of a large set of coregulatory proteins. These transcription cofactors regulate, either positively or negatively, chromatin structure and transcription initiation. One of the first proteins to be identified as a hormone-recruited cofactor was RIP140. Despite its recruitment by agonist-liganded receptors, RIP140 exhibits a strong transcriptional repressive activity which involves several inhibitory domains and different effectors. Interestingly, the RIP140 gene, located on chromosome 21 in humans, is finely regulated at the transcriptional level by various nuclear receptors. In addition, the protein undergoes several post-translational modifications which control its repressive activity. Finally, experiments performed in mice devoid of the RIP140 gene indicate that this transcriptional cofactor is essential for female fertility and energy homeostasis. RIP140 therefore appears to be an important modulator of nuclear receptor activity which could play major roles in physiological processes and hormone-dependent diseases.
RESUMEN
Receptor interacting protein (RIP) 140 is a negative transcriptional regulator of nuclear hormone receptors which is required for the maintenance of energy homeostasis and ovulation. Despite its recruitment by agonist-liganded receptors, this protein exhibits a strong repressive activity which was initially attributed to competition with coactivator binding on nuclear receptors. However, RIP140 also exerts active repression implicating the Carboxyl-terminal binding proteins (CtBPs) and histone deacetylases (HDACs). We recently demonstrated that the Carboxyl-terminal region of the molecule contains two additional silencing domains which require post-translational modifications to be fully active. In human breast cancer cells, RIP140 expression is up-regulated at the transcriptional level by various ligands of nuclear receptors. We have recently cloned the human RIP140 gene and defined the mechanism of its regulation by estrogens. In order to better characterize the role of RIP140 in hormone signaling, we have studied its interaction with the androgen receptor and demonstrated its ability to repress transcriptional regulation by androgens. RIP140 also inhibits transactivation by estrogen receptor-related receptors (ERRalpha, beta and gamma) on natural or artificial reporter genes containing different types of response elements. Surprisingly, RIP140 positively regulates ERR transactivation when the receptors are recruited to target promoters through interaction with the Sp1 transcription factor and this effect could involve titration of histone deacetylases. Altogether, these results underline that transcriptional regulation of hormone signaling by the cofactor RIP140 involves complex mechanisms relying on multiple domains and partners.
Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/fisiología , Hormonas/fisiología , Proteínas Nucleares/fisiología , Transducción de Señal , Humanos , Proteína de Interacción con Receptores Nucleares 1 , Receptores de Estrógenos/metabolismo , Transcripción GenéticaRESUMEN
The androgen receptor (AR) is a ligand-activated transcription factor that controls growth and survival of prostate cancer cells. In the present study, we investigated the regulation of AR activity by the receptor-interacting protein 140 (RIP140). We first showed that RIP140 could be coimmunoprecipitated with the receptor when coexpressed in 293T cells. This interaction appeared physiologically relevant because chromatin immunoprecipitation assays revealed that, under R1881 treatment, RIP140 could be recruited to the prostate-specific antigen encoding gene in LNCaP cells. In vitro glutathione S-transferase pull-down assays provided evidence that the carboxy-terminal domain of AR could interact with different regions of RIP140. By means of fluorescent proteins, we demonstrated that ligand-activated AR was not only able to translocate to the nucleus but also to relocate RIP140 from very structured nuclear foci to a diffuse pattern. Overexpression of RIP140 strongly repressed AR-dependent transactivation by preferentially targeting the ligand binding domain-dependent activity. Moreover, disruption of RIP140 expression induced AR overactivation, thus revealing RIP140 as a strong AR repressor. We analyzed its mechanism of transrepression and first demonstrated that different regions of RIP140 could mediate AR-dependent repression. We then showed that the carboxy-terminal end of RIP140 could reverse transcriptional intermediary factor 2-dependent overactivation of AR. The use of mutants of RIP140 allowed us to suggest that C-terminal binding protein played no role in RIP140-dependent inhibition of AR activity, whereas histone deacetylases partly regulated that transrepression. Finally, we provided evidence for a stimulation of RIP140 mRNA expression in LNCaP cells under androgen treatment, further emphasizing the role of RIP140 in androgen signaling.
Asunto(s)
Antagonistas de Receptores Androgénicos , Proteínas Nucleares/metabolismo , Proteínas Adaptadoras Transductoras de Señales , Oxidorreductasas de Alcohol , Animales , Células COS , Compartimento Celular , Chlorocebus aethiops , Cricetinae , Proteínas de Unión al ADN/metabolismo , Regulación de la Expresión Génica , Histona Desacetilasas/metabolismo , Humanos , Metribolona/farmacología , Proteína de Interacción con Receptores Nucleares 1 , Fosfoproteínas/metabolismo , Unión Proteica , ARN Mensajero/metabolismo , Células Tumorales Cultivadas , Regulación hacia Arriba/efectos de los fármacosRESUMEN
We have investigated the effects of receptor-interacting protein 140 (RIP140) on transcriptional regulation by estrogen receptor-related receptors (ERRs). We first show that RIP140 inhibits transactivation by ERRalpha, beta, and gamma on natural or artificial reporter genes containing different types of response elements. This repression correlates with a strong in vitro binding between several regions of RIP140 and the three ERR isoforms. Surprisingly, although RIP140 inhibits transactivation of the thyroid hormone receptor-alpha gene by ERRbeta, it significantly increases its regulation by ERRalpha and ERRgamma. Mutagenesis and transient transfections in SL2 cells indicate that thyroid hormone receptor-alpha promoter expression involved Sp1 sites. In support of this observation, we demonstrate that RIP140 also positively regulates ERRs transactivation of other known Sp1 targets such as the p21 gene. This effect requires the two proximal Sp1 binding sites of the promoter and is partially dependent on the activation function 2 domain of ERRs. Finally, we provide evidences for a role of histone deacetylases in the regulation of p21 promoter by RIP140. Altogether, these data indicate that RIP140 differentially regulates ERR activity depending on the target sequence on the promoters.
Asunto(s)
Proteínas Nucleares/fisiología , Receptores Citoplasmáticos y Nucleares/metabolismo , Receptores de Estrógenos/metabolismo , Activación Transcripcional/genética , Proteínas Adaptadoras Transductoras de Señales , Células Cultivadas , Histona Desacetilasas/metabolismo , Humanos , Mutagénesis , Proteínas Nucleares/genética , Proteínas Nucleares/metabolismo , Proteína de Interacción con Receptores Nucleares 1 , Regiones Promotoras Genéticas , Estructura Terciaria de Proteína/genética , Estructura Terciaria de Proteína/fisiología , Receptores Citoplasmáticos y Nucleares/genética , Receptores de Estrógenos/genética , Factor de Transcripción Sp1/metabolismo , Receptores alfa de Hormona Tiroidea/genética , Transfección , Factor Trefoil-1 , Proteínas Supresoras de Tumor/genética , Receptor Relacionado con Estrógeno ERRalfaRESUMEN
Nuclear hormone receptors belong to a superfamily of ligand-activated transcription factors which regulate fundamental physiological processes. Their activity is controlled by a large number of coregulatory proteins which are, in most cases, recruited by nuclear receptors in the presence of ligand. RIP140 (receptor interacting protein of 140 kDa) was one of the first transcription cofactors to be identified almost ten years ago. This molecule is an atypical cofactor which interacts with agonist-liganded nuclear receptors but negatively regulates their transactivation potential. RIP140 exhibits nine leucine-rich motifs (LxxLL) which mediate the specific docking on the nuclear receptor ligand-binding domain. Transcription repression exerted by this cofactor implicates different mechanisms. Not only it involves a competition with coactivators such as those belonging to the p160 family, but also relies on active intrinsic repression through at least four different domains which allow recruitement of downstream repressors such as histone deacetylases (HDACs) or C-terminal binding proteins (CtBPs). The biological role of RIP140 has been investigated by disrupting the gene in mice. The lack of RIP140 expression in ovaries prevents follicle rupture and ovulation, rising to female infertility. In addition, this cofactor is also required for the control of fat storage and utilization through the regulation of genes involved in thermogenesis. Finally, RIP140 could play a role in the hormonal control of cancer cell proliferation by negatively regulating the activity of estrogen and retinoic acid receptors which are key actors in cancer growth. Interestingly, both estrogens and retinoic acid regulate RIP140 gene expression, revealing an increased level of complexity. In conclusion, RIP140 is an atypical transcription inhibitor which, by repressing nuclear hormone receptor activity, plays fundamental physiopathological roles.
Asunto(s)
Hormonas/fisiología , Proteínas Nucleares/fisiología , Receptores de Estrógenos/fisiología , Proteínas Adaptadoras Transductoras de Señales , Animales , Femenino , Humanos , Masculino , Proteínas Nucleares/genética , Proteína de Interacción con Receptores Nucleares 1 , Receptores de Estrógenos/genética , Transcripción GenéticaRESUMEN
Estrogen receptor (ER) function is mediated by multi-domain co-regulator proteins. A fluorescently labelled fragment of the human PGC-1alpha co-regulator (residues 91-408) bearing the two motifs most strongly implicated in interactions with nuclear receptors (NR box2 and NR box3), was used to characterize in vitro binding of PGC-1alpha to ER. Anisotropy measurements revealed that the affinity of this PGC-1alpha fragment for human ERalpha and beta was fairly strong in the presence of estradiol (approximately 5 nM), and that unlike a similar fragment of SRC-1 (570-780), PGC-191-408 exhibited ligand-independent interactions with ER, particularly with ERbeta (Kd approximately 30 nM). Competition experiments of the complex between ERalpha and fluorescently labelled PGC-1 91-408 with unlabelled SRC-1 570-780 showed that PGC-1 91-408 was an efficient competitor of SRC-1 570-780, while the inverse was not true, underscoring their distinct modes of binding. The anisotropy data provide strong evidence for a ternary complex between ERalpha, SRC-1 570-780 and PGC-1 91-408. GST-pull-down experiments with deletion mutants of ERalpha revealed that the constitutive binding of PGC-1 91-408 requires the presence of the linker domain between the DNA binding and ligand binding domains (DBD and LBD). Homology modeling studies of the different regions of full length PGC-1alpha confirmed the lack of compact tertiary structure of the N-terminal region bearing the NR box motifs, and suggested a slightly different mode of interaction compared to the NR box motifs of SRC-1. They also provided reasonable structural models for the coiled-coil dimerization motif at residues 633-675, as well as the C-terminal putative RNA binding domain, raising important questions concerning the stoichiometry of its complex with the nuclear receptors.
Asunto(s)
Receptor alfa de Estrógeno/metabolismo , Receptor beta de Estrógeno/metabolismo , Proteínas de Choque Térmico/química , Proteínas de Choque Térmico/metabolismo , Factores de Transcripción/química , Factores de Transcripción/metabolismo , Anisotropía , Dimerización , Receptor alfa de Estrógeno/genética , Receptor beta de Estrógeno/genética , Proteínas de Choque Térmico/genética , Histona Acetiltransferasas , Humanos , Ligandos , Modelos Biológicos , Modelos Moleculares , Mutación/genética , Coactivador 1 de Receptor Nuclear , Coactivador 1-alfa del Receptor Activado por Proliferadores de Peroxisomas gamma , Unión Proteica , Estructura Terciaria de Proteína , Espectrometría de Fluorescencia , Termodinámica , Volumetría , Factores de Transcripción/genética , Transcripción Genética/genéticaRESUMEN
Estrogens are steroid hormones, which act through specific nuclear estrogen receptors (ERalpha and ERbeta) and are important regulators of breast cancer growth. These receptors control gene expression by recruiting transcriptional cofactors that exhibit various enzymatic activities such as histone acetyltransferase or histone deacetylase (HDAC) which target histone as well as non-histone substrates. The ERalpha itself and some of the transcriptional regulators have been shown to be acetylated proteins. Research performed over the last decade has highlighted the role of HDAC inhibitors (HDACi) as modulators of transcriptional activity and as a new class of therapeutic agents. In human cancer cells, inhibition of HDACs controls the expression of the ERalpha gene and the transcriptional activity in response to partial antiestrogens such as 4-hydroxytamoxifen. Various HDACi strongly inhibit breast cancer cell proliferation and ERalpha-negative (ER-) appear less sensitive than ERalpha-positive (ER+) cell lines. p21WAF1/CIP1 gene expression, in relation with ERalpha levels, could play a role in this differential response of breast cancer cells to hyperacetylating agents.
Asunto(s)
Neoplasias de la Mama/metabolismo , Inhibidores Enzimáticos/farmacología , Estrógenos/fisiología , Inhibidores de Histona Desacetilasas , Receptores de Estrógenos/metabolismo , Acetilación/efectos de los fármacos , Neoplasias de la Mama/enzimología , Neoplasias de la Mama/patología , Moduladores de los Receptores de Estrógeno/farmacología , Receptor alfa de Estrógeno , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Receptores de Estrógenos/genética , Transducción de Señal/fisiología , Células Tumorales CultivadasRESUMEN
In this study, we have investigated the role of C-terminal binding proteins (CtBPs) and histone deacetylases (HDACs) in the repressive activity of the nuclear receptor cofactor Receptor-Interacting Protein 140 (RIP140). We have defined the interaction of both CtBP1 and CtBP2 with RIP140 and delineated two motifs (PIDLS and PINLS) differentially required for in vitro interaction. Using different approaches (titration of endogenous CtBPs, mutagenesis and transfection in CtBP knock-out cells), we find that recruitment of CtBPs only partially explains the negative regulation exerted by RIP140. We then demonstrate that RIP140 associates in vitro not only with class I HDACs but also with class II enzymes such as HDAC5. This interaction mainly involves the N-terminus of RIP140 (residues 27-199) and two domains of HDAC5. Moreover, the two proteins functionally interfere in transfection experiments, and confocal microscopy indicates that they co-localize in the nucleus. Interestingly, using the specific HDAC inhibitor trichostatin A, we show that HDAC activity is dispensable for active transrepression by RIP140. Finally, we demonstrate that the C-terminal region of RIP140 contains two additional silencing domains and confers strong active transrepression independently of HDAC activity and CtBPs. Altogether, these data indicate that transcriptional inhibition by the cofactor RIP140 involves complex mechanisms relying on multiple domains and partners.
Asunto(s)
Silenciador del Gen , Proteínas Nucleares/química , Proteínas Nucleares/metabolismo , Proteínas Represoras/química , Proteínas Represoras/metabolismo , Proteínas Adaptadoras Transductoras de Señales , Oxidorreductasas de Alcohol , Animales , Línea Celular , Proteínas de Unión al ADN/genética , Proteínas de Unión al ADN/fisiología , Estradiol/farmacología , Histona Desacetilasas/fisiología , Humanos , Ratones , Ratones Noqueados , Proteína de Interacción con Receptores Nucleares 1 , Fosfoproteínas/genética , Fosfoproteínas/fisiología , Estructura Terciaria de Proteína , Transcripción GenéticaRESUMEN
Many hormones exert their effects through specific nuclear receptors which belong to a superfamily of ligand-activated transcription factors. These receptors control target gene expression through the recruitment of different cofactors acting as transcription activation or repression mediators, generally as parts of multiprotein complexes. The importance and the role in physiopathology of these different cofactors only begin to be defined. Different types of alterations affecting genes coding nuclear receptor transcription cofactors have indeed been described in cancer. The most important examples are gene amplification that leads to overexpression and gene mutations or translocations introducing qualitative modifications. This paper aims at bringing together the corresponding literature and focuses on gene alterations observed in solid tumors.